Stem Cell Transplant to Treat Patients With Systemic Sclerosis

This study has been completed.
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by:
Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00058578
First received: April 8, 2003
Last updated: April 9, 2007
Last verified: April 2007
  Purpose

Systemic Sclerosis is a disease that may be caused by the immune system reacting against skin and certain organs. It is possible, that by changing the immune system we can modify the progression of this disease.

Stem cells are created in the bone marrow. They mature into different types of blood cells that are needed including red blood cells, white blood cells, and platelets. In this study, we will stimulate the bone marrow to make extra stem cells. Next we will collect the stem cells, select specific cells, and store them. We will then give high dose chemotherapy that will destroy the patients immune system. We will then give back the selected stem cells we collected. We believe that these selected stem cells may be able to "re-create" the immune system without the portion that causes Systemic Sclerosis.

The purpose of this study is to try to discover if stem cell transplantation can help patients with Systemic Sclerosis. We will also try to learn what the side effects are of this treatment in patients with Systemic Sclerosis. We hope that this treatment will help to relieve the symptoms patients are experiencing, although we do not know if it will.


Condition Intervention Phase
Systemic Sclerosis
Drug: Cyclophosphamide
Drug: Mesna
Drug: G-CSF
Procedure: Leukopheresis
Procedure: Total Body Irradiation
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Estimated Enrollment: 24
Study Start Date: June 1999
Estimated Study Completion Date: June 2004
Detailed Description:

Before the transplant the research participant will receive daily G-CSF (Neupogen) for 5-6 days. This medication will help to stimulate the production of white blood cells (WBC) that will be used for the stem cell transplant. The G-CSF will be given as an injection into the arm.

If G-CSF does not stimulate the stem cells sufficiently, the patient will receive a single dose of drug called cyclophosphamide (chemotherapy) intravenously (into a vein). This drug will cause the blood cell counts to fall. A drug called MESNA will also be given to help protect the bladder from the Cyclophosphamide. After completing chemotherapy, patients will be started on G-CSF again until blood cell counts reach a certain level, at which time the patient will undergo leukopheresis. Leukopheresis is a procedure where blood is removed from one arm, pumped into a machine where the white blood cells are separated from most of the other cells and then returned through the same needle or through a needle in the other arm. This procedure usually takes 3 to 4 hours a day for up to 4 days in a row, depending on how many cells are collected each time.

After collection of the white blood cells, special agents (called monoclonal antibodies) will be used in the laboratory to select out certain types of white blood cells (CD34+ cells). The blood cells will be separated on a machine which picks out stem cells.

After leukopheresis, patients will receive drugs called cyclophosphamide and Mesna. They will also receive a drug called Atgam and radiation treatment to the entire body. This treatment will kill most of the blood forming cells in the bone marrow. We will then give the CD34+ cells that were collected during leukopheresis.

After the transplant patients will be followed closely, the same as any patient who receives a stem cell transplant. This follow-up will involve blood tests to see how the body is recovering after the chemotherapy and radiation, and a bone marrow aspiration once a year for 2 years.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria:

  • Patients aged < 60 years
  • Patients must have either one major or 2 minor criteria for systemic sclerosis as per the criteria developed during the Scleroderma Criteria Cooperative Study.
  • Rapidly progressive diffuse skin disease without other organ involvement (at least one of the following):

    • Scl-70 positive
    • Rodnam Skin score 16
    • With/without U3RNP antibodies; RNA polymerases 1-111 OR
  • Internal Organ Involvement (at least one of the following):

    • Renal Proteinuria > 500mg/dl
    • Creatinine clearance > 50ml/min.
    • Blood pressure controlled to ≤ 160/110
    • Interstitial lung disease on high resolution CT
    • Hypoxemia (pO2 > 70 mmHg)
    • FVC > 50%
    • DLCO > 45%
    • Cardiac Disease
    • Myocarditis
    • Pericarditis
    • Coronary Artery Ejection Fraction > 30%
  • Patients must meet the following hematological parameters:

    • Have an ANC > 500/mm3
    • Have a platelet count > 120 x lO9/l
    • Have a hemoglobin > 10g/dl

Exclusion Criteria:

  • Patients > 60 years
  • Patients with pulmonary, cardiac, hepatic, or renal impairment which would limit their ability to receive cytoreductive therapy and compromise their survival. This should include patients with any of the following:

    • Severe Lung Disease
    • Hypoxemia (pO2 £70 mmHg)
    • FVC of < 50%
    • DLCO of < 45%
    • Cardiac Disease
    • Ejection fraction < 30%
    • Uncontrolled arrhythmias
    • Cor. Pulmonale
    • Pulmonary hypertension (mPAP >/=60 mmHg)
    • Loss of digits or vascular access secondary to Raynaud’s ischemia
    • History of oliguric renal failure or episode of renal crisiswith Glomerular filtration rate < 50ml/min Creatinine. Weight loss > 20% baseline since first involvement of gastrointestinal tract (midgut); or any patient requiring hyperalimentation prior to transplant because of gut dysfunction related to systemic sclerosis
    • SGOT/bilirubin > 2 x UPN on 2 repeated tests
    • Has active uncontrolled infection
    • Is sero-positive for HIV
    • Has demonstrated lack of compliance with prior medical care
    • Has active malignancy
    • Life expectancy is severely limited by illness other than scleroderma
    • Has evidence of myelodysplasia or prior extensive chemotherapy
    • Has uncontrolled hypertension
    • Positive pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00058578

Locations
United States, Texas
The Methodist Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00058578     History of Changes
Other Study ID Numbers: H7157, Systemic Sclerosis
Study First Received: April 8, 2003
Last Updated: April 9, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Sclerosis
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Cyclophosphamide
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists

ClinicalTrials.gov processed this record on September 18, 2014